Inventor · disambiguated record
John Diener
Also filed as: DIENER JOHN · DIENER JOHN L · DIENER JOHN LOUIS
35 granted patents·22 pending applications·337 citations·filing 2003–2025
97Inventor score
Files withNOVARTIS AG14ARCHEMIX CORP10DIENER JOHN L6ARROWHEAD PHARMACEUTICALS INC3TECTONIC OPERATING COMPANY INC3
Top patents by PatentIndex Score
57 records- 0196US7767803B2Stabilized aptamers to PSMA and their use as prostate cancer therapeuticsARCHEMIX CORP·Filed 2006·Granted Aug 3, 2010·63 cites·18 claims
- 0294US8101385B2Materials and methods for the generation of transcripts comprising modified nucleotidesCLOAD SHARON·Filed 2007·Granted Jan 24, 2012·113 cites·24 claims
- 0393US7538211B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX CORP·Filed 2005·Granted May 26, 2009·33 cites·7 claims
- 0492US11466048B23′ end caps, 5′ end caps and combinations thereof for therapeutic RNANOVARTIS AG·Filed 2020·Granted Oct 11, 2022·3 cites·5 claims
- 0592US7803931B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX CORP·Filed 2005·Granted Sep 28, 2010·19 cites·5 claims
- 0692US7566701B2Aptamers to von Willebrand Factor and their use as thrombotic disease therapeuticsARCHEMIX CORP·Filed 2005·Granted Jul 28, 2009·30 cites·19 claims
- 0788US10676499B23′ end caps, 5′ end caps and combinations thereof for therapeutic RNANOVARTIS AG·Filed 2015·Granted Jun 9, 2020·6 cites·2 claims
- 0888US7998939B2Aptamers that bind thrombin with high affinityARCHEMIX CORP·Filed 2006·Granted Aug 16, 2011·16 cites·30 claims
- 0986US7960102B2Regulated aptamer therapeuticsARCHEMIX CORP·Filed 2005·Granted Jun 14, 2011·6 cites·8 claims
- 1085US7998940B2Aptamers to von Willebrand factor and their use as thrombotic disease therapeuticsARCHEMIX CORP·Filed 2009·Granted Aug 16, 2011·6 cites·19 claims
- 1183US8598327B2Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeuticsSCHAUB ROBERT·Filed 2011·Granted Dec 3, 2013·10 cites·19 claims
- 1282US7589073B2Aptamers to von Willebrand Factor and their use as thrombotic disease therapeuticsARCHEMIX CORP·Filed 2006·Granted Sep 15, 2009·4 cites·40 claims
- 1381US8105813B2Materials and methods for the generation of fully 2′-modified nucleic acid transcriptsDIENER JOHN L·Filed 2006·Granted Jan 31, 2012·8 cites·11 claims
- 1479US12264188B2Relaxin-2 fusion proteinsTECTONIC OPERATING COMPANY INC·Filed 2024·Granted Apr 1, 2025·1 cites·21 claims
- 1579US8039443B2Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsARCHEMIX CORP·Filed 2004·Granted Oct 18, 2011·5 cites·3 claims
- 1678US9752152B2Organic compositions to treat beta-ENaC-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 5, 2017·1 cites·15 claims
- 1778US7579450B2Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeuticsARCHEMIX CORP·Filed 2005·Granted Aug 25, 2009·4 cites·20 claims
- 1876US8252913B2Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeuticsSCHAUB ROBERT G·Filed 2010·Granted Aug 28, 2012·4 cites·36 claims
- 1974US12410255B2Natriuretic peptide receptor 1 antibodies and methods of useNOVARTIS AG·Filed 2023·Granted Sep 9, 2025·0 cites·12 claims
- 2074US10100316B2Aptamers comprising CPG motifsEPSTEIN DAVID·Filed 2004·Granted Oct 16, 2018·4 cites·14 claims
- 2173US2023183286A1Novel 3' end caps, 5' end caps and combinations thereof for therapeutic rnaNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2271US10550391B2Organic compositions to treat beta-ENaC-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 4, 2020·0 cites·15 claims
- 2369US2024293508A1Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signalingNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2468US10081811B2Organic compositions to treat Beta-ENaC-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 25, 2018·0 cites·15 claims
- 2568US9303262B2Methods for identifying aptamer regulatorsWILSON CHARLES·Filed 2003·Granted Apr 5, 2016·1 cites·8 claims
- 2666US9080175B2Organic compositions to treat Beta-ENaC-related diseasesARROWHEAD RES CORP·Filed 2013·Granted Jul 14, 2015·0 cites·15 claims
- 2764US8598335B2Organic compositions to treat Beta-ENaC-related diseasesDE FOUGEROLLES ANTONIN·Filed 2012·Granted Dec 3, 2013·0 cites·15 claims
- 2863US11066469B2Natriuretic peptide receptor 1 antibodies and methods of useNOVARTIS AG·Filed 2020·Granted Jul 20, 2021·0 cites·17 claims
- 2963US8344130B2Organic compositions to treat Beta-ENaC-related diseasesNOVARTIS AG·Filed 2012·Granted Jan 1, 2013·0 cites·21 claims
- 3063US8344131B2Organic compositions to treat beta-ENaC-related diseasesNOVARTIS AG·Filed 2012·Granted Jan 1, 2013·0 cites·21 claims
- 3163US8344129B2Organic compositions to treat Beta-ENaC-related diseasesNOVARTIS AG·Filed 2012·Granted Jan 1, 2013·0 cites·17 claims
- 3263US2015140120A1Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsARCHEMIX LLC·Filed 2014·Application pending·0 cites
- 3362US11963999B2Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteinsNOVARTIS AG·Filed 2019·Granted Apr 23, 2024·0 cites·2 claims
- 3462US2022356242A1Natriuretic peptide receptor 1 antibodies and methods of useNOVARTIS AG·Filed 2021·Application pending·0 cites
- 3561US9376683B2Organic compositions to treat beta-ENaC-related diseasesARROWHEAD RES CORP·Filed 2015·Granted Jun 28, 2016·0 cites·13 claims
- 3661US8344127B2Organic compositions to treat beta-ENaC-related diseasesNOVARTIS AG·Filed 2011·Granted Jan 1, 2013·0 cites·21 claims
- 3758US12509497B2Relaxin-2 fusion protein analogs and methods of using sameTECTONIC OPERATING COMPANY INC·Filed 2022·Granted Dec 30, 2025·0 cites·12 claims
- 3857US8853376B2Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsMCCAULEY DILARA·Filed 2011·Granted Oct 7, 2014·0 cites·9 claims
- 3955US2016053266A1Stabilized Aptamers to Platelet Derived Growth Factor and Their Use as Oncology TherapeuticsARCHEMIX LLC·Filed 2015·Application pending·0 cites
- 4053US2024052042A1Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereofNOVARTIS AG·Filed 2021·Application pending·0 cites
- 4153US2004110235A1Regulated aptamer therapeuticsFiled 2003·Application pending·0 cites
- 4252US2025223370A1Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodiesNOVARTIS AG·Filed 2023·Application pending·0 cites
- 4352US2009053138A1Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology TherapeuticsPREISS JEFFREY R·Filed 2005·Application pending·0 cites
- 4452US2024260549A1Methods and systems for aquacultureVERTICAL OCEANS PTD LTD·Filed 2024·Application pending·0 cites
- 4550US8461318B2Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeuticsSCHAUB ROBERT·Filed 2011·Granted Jun 11, 2013·0 cites·1 claims
- 4650US2004137429A1Therapeutic aptamers having binding specificity to gp41 of HIVFiled 2003·Application pending·0 cites
- 4749US2025333467A1Relaxin-2 fusion protein analogs and methods of using sameTECTONIC OPERATING COMPANY INC·Filed 2025·Application pending·0 cites
- 4849US2005124565A1Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsFiled 2004·Application pending·0 cites
- 4946US2009082555A1Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeuticsDIENER JOHN L·Filed 2008·Application pending·0 cites
- 5045US2007066551A1Aptamer medicinal chemistryKEEFE ANTHONY D·Filed 2005·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →